Have a look at this recently published paper by Ron Keizer and colleagues;
will answer your question.
"Incorporation of concentration data below the limit of quantification in
population pharmacokinetic analyses". Keizer et al, Pharmacol Res Perspect,
On Fri, Oct 2, 2015 at 4:22 PM, Moffett, Brady S. <bsmoffet_at_txch.org> wrote=
> I am working with TDM data and am wondering when to use the M3 method for
> dealing with BLQ data, or, when to just exclude data?
> For instance: If I have <1% BLQ data in a large dataset (~1000 patients)=
> should I just exclude those patients/values? If I just have one patient
> with one value BLQ, is it worth using the M3 method for that one patient?
> Is there a breakpoint for which using these methods does/does not make a
> Thanks in advance…
> CONFIDENTIALITY NOTICE:
> The information in this e-mail may be confidential and/or
> privileged. If you are not the intended recipient or an
> authorized representative of the intended recipient, you
> are hereby notified that any review, dissemination, or
> copying of this e-mail and its attachments, if any, or
> the information contained herein is prohibited. If you
> have received this e-mail in error, please immediately
> notify the sender by return e-mail and delete this e-mail
> from your computer system. Thank you.
Ahmed Abbas Suleiman, MSc
PhD Candidate at Bonn University
Institute of Pharmacology - Clinical Pharmacology Unit
Hospital of the University of Cologne
Gleueler Str. 24, 50931 Cologne,
Received on Fri Oct 02 2015 - 12:05:36 EDT
This archive was generated by hypermail 2.3.0
: Fri Sep 27 2019 - 16:46:26 EDT